<DOC>
	<DOCNO>NCT01155570</DOCNO>
	<brief_summary>The survey conduct regard follow aspect treatment Humira ( adalimumab ) patient psoriasis vulgaris psoriatic arthritis receive drug : - unknown adverse drug reaction , especially clinically significant adverse reaction - incidence condition occurrence adverse reaction clinical set - factor may affect safety effectiveness Humira .</brief_summary>
	<brief_title>Special Investigation Patients With Psoriasis Vulgaris Psoriatic Arthritis ( All Patients Investigation )</brief_title>
	<detailed_description>This study non-interventional , open-labeled , all-cases , central registration method , post marketing observational study Humira prescribe patient psoriasis vulgaris and/or psoriatic arthritis routine medical practice . When investigator prescribe Humira eligible patient provide informed consent , fill registration form send registration center via postal mail . At end 24-week observation period , investigator fill case report form patient describe finding study period , provide complete form medical representative . Even Humira treatment reason discontinue , investigator follow participant 24 week first administration Humira , fill case report form participant end 24-week period . Some participant enter study study NCT00647400 ( M04-702 ) , Phase III extension study Humira ( adalimumab ) Japan .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>All patient receive Humira treatment psoriasis vulgaris psoriatic arthritis respond conventional treatment evaluate . Eligible patient respond least one type conventional systemic treatment ( include ultraviolet therapy ) skin lesion involve 10 % body surface area patient intractable eruption joint signs/symptoms . Contraindications accord Package Insert include patient follow : serious infection tuberculosis history hypersensitivity ingredient Humira demyelinate disease history demyelinate disease congestive cardiac failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>